Tag Archives: another

BMS deal quest gets a boost as Celgene swats aside another Revlimid patent challenge

Much of the investor doubt surrounding Bristol-Myers Squibb’s $ 74 billion Celgene buyout centers on the multiple myeloma blockbuster Revlimid—namely, whether its remaining patents can stand up to legal challenges. But the companies just scored a win in that department. Thursday, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) decided not… Read More »

Killings of transgender people in the US saw another high year

As deputy director at the Transgender Law Center based in Oakland, California, she has met many community members who have the same experience. “Death, profound loss, the violence that surrounds us, it’s constant. It’s a significant part of my transgender experience.” Despite an all-time high in trans-visibility, with celebrities such as Caitlyn Jenner and Laverne… Read More »